How Jeffrey A, Jazaeri Amir A, Fu Siqing, Rodon Ahnert Jordi, Gong Jing, Stephen Bettzy, Ferreira Dalla Pria Hanna, Bhosale Priya, Johnson Amber, Yuan Ying, Meric-Bernstam Funda, Naing Aung
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2022 Jul 29;14(15):3695. doi: 10.3390/cancers14153695.
Recurrent microsatellite stable (MSS) endometrial cancer has poor response to conventional therapy and limited efficacy with immune checkpoint monotherapy. We conducted a retrospective study of recurrent MSS endometrial cancer patients enrolled in immunotherapy-based clinical trials at MD Anderson Cancer Center between 1 January 2010 and 31 December 2019. Patients were evaluated for radiologic response using RECIST 1.1 criteria, progression-free survival (PFS), and overall survival (OS). Thirty-five patients were treated with immune checkpoint inhibitors: 8 with monotherapy, 17 with immunotherapy (IO) in combination with another IO-only, and 10 with IO in combination with non-IO therapy. Among those treated with combination IO plus non-IO therapy, one had a partial response but 50% had clinical benefit. Patients who received combination IO plus non-IO therapy had improved PFS compared to those who received monotherapy (HR 0.56, 95% CI 0.33-0.97; = 0.037) or combination IO-only therapy (HR 0.36, 95% CI 0.15-0.90; = 0.028) and had improved OS when compared to monotherapy after adjusting for prior lines of therapy (HR 0.50, 95% CI 0.27-0.95; = 0.036). The potential beneficial clinical outcomes of combination IO plus non-IO therapy in MSS endometrial cancer should be validated in a larger study.
复发性微卫星稳定（MSS）子宫内膜癌对传统治疗反应不佳，免疫检查点单药治疗疗效有限。我们对2010年1月1日至2019年12月31日期间在MD安德森癌症中心参加基于免疫治疗的临床试验的复发性MSS子宫内膜癌患者进行了一项回顾性研究。使用RECIST 1.1标准、无进展生存期（PFS）和总生存期（OS）对患者进行放射学反应评估。35例患者接受了免疫检查点抑制剂治疗：8例接受单药治疗，17例接受免疫治疗（IO）联合另一种仅用IO的治疗，10例接受IO联合非IO治疗。在接受IO联合非IO治疗的患者中，1例有部分缓解，但50%有临床获益。与接受单药治疗的患者相比（HR 0.56，95%CI 0.33-0.97；P = 0.037）或仅接受IO联合治疗的患者相比（HR 0.36，95%CI 0.15-0.90；P = 0.028），接受IO联合非IO治疗的患者PFS有所改善，在调整先前治疗线数后，与单药治疗相比，OS也有所改善（HR 0.50，95%CI 0.27-0.95；P = 0.036）。IO联合非IO治疗在MSS子宫内膜癌中潜在的有益临床结果应在更大规模的研究中得到验证。
